首页> 外文期刊>Stem Cell Discovery >Human umbilical cord blood-derived mononuclear cell transplantation for umbilical hernia and hepatic hydrothorax in primary biliary cirrhosis
【24h】

Human umbilical cord blood-derived mononuclear cell transplantation for umbilical hernia and hepatic hydrothorax in primary biliary cirrhosis

机译:人脐血来源的单核细胞移植治疗原发性胆汁性肝硬化的脐疝和肝胸水

获取原文
           

摘要

Cell therapy was proposed as a potential treatment intervention for liver cirrhosis recently due to the fact that the therapeutic protocol for primary biliary cirrhosis (PBC)-associated refractory umbilical hernia and hepatic hydrothorax is not well defined currently. We report herein the case of a 58-year-old woman who received routine treatments for PBC, which developed into an incarcerated hernia and uncontrolled hydrothorax. This subject’s condition was significantly improved and maintained stable condition after receiving human umbilical cord blood-derived mononuclear cell (CBMC) transplantation. Consequently, this new strategy may be a potential treatment option for the refractory umbilical hernia and hydrothorax caused by PBC. However, sufficient data from large-scale controlled and double-blinded clinical trials are needed to further confirm the treatment efficacy and longterm safety before this cell transplantation can be used as a regular therapy for liver cirrhosis.
机译:由于目前尚不明确原发性胆汁性肝硬化(PBC)相关的难治性脐疝和肝胸水的治疗方案,因此细胞疗法被提议作为肝硬化的潜在治疗手段。我们在此报告了一名58岁的女性,该患者接受了PBC的常规治疗,该疾病发展为嵌顿性疝气和不受控制的胸膜积水。接受人脐带血来源的单核细胞(CBMC)移植后,该受试者的状况得到了明显改善,并保持了稳定的状态。因此,该新策略可能是治疗由PBC引起的难治性脐疝和胸腔积水的潜在治疗选择。但是,需要足够的大规模对照和双盲临床试验数据,才能进一步确认治疗效果和长期安全性,然后才能将该细胞移植用作肝硬化的常规治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号